1. Healthcare

  2. •

    Biotechnology
Senomyx, Inc.

Senomyx, Inc.

SNMX
Senomyx, Inc.US flagNASDAQ
1.49
USD
- -
- -
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
0.36
0.41
0.6
0.56
0.5
0.76
0.79
0.78
0.72
0.65
0.57
0.51
0.62
0.55
Basic EPS, GAAP
-0.77
-0.77
-0.72
-0.88
-0.85
-0.28
-0.22
-0.23
-0.29
-0.29
-0.29
-0.24
-0.03
-0.05
Free Cash Flow per Basic Share
-0.61
-0.46
-0.51
-0.8
-0.32
0.55
-0.44
-0.35
-0.25
-0.33
-0.2
-0.26
0.03
0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4.02
-4.27
-4.92
-5.75
-6.54
-5.64
-5.6
-5.78
-5.97
-5.98
-6.08
-6.21
-5.92
-5.95
Tangible Book Value per Share
3.18
2.33
1.87
1.21
0.57
0.85
0.75
0.64
0.48
0.55
0.44
0.33
0.4
0.29
Basic Weighted Avg Shares
26
30
30
31
31
38
40
40
41
43
44
45
47
48
Sales/Revenue/Turnover
9
12
18
17
16
29
31
31
29
28
25
23
29
26
Operating Margin (%)
-225.62
-219.93
-138.45
-164.21
-170.02
-38.33
-28.25
-29.55
-40.75
-44.06
-51
-46.7
-4.55
-9.69
Depreciation Expense
3
2
2
4
2
2
3
3
3
2
1
1
1
1
Net Income, GAAP
-20
-23
-22
-27
-26
-11
-9
-9
-12
-12
-13
-11
-1
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-211.29
-188.53
-119.82
-156.9
-168.69
-37.15
-27.84
-29.34
-40.63
-43.92
-50.83
-46.38
-4.31
-9.11
Working Capital
80
65
52
32
18
33
36
22
17
20
20
14
20
15
LT Debt
- -
9
8
7
6
5
4
3
2
1
2
1
- -
- -
Total Equity
82
69
57
37
18
32
30
26
20
24
20
15
19
14
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
61
42
58

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
25
22
19
Cash, Cash Equivalents & STI
16
18
15
Accounts Receivable, Net
7
2
2
Inventories
2
2
2
Total Current Liabilities
5
7
4
Payables & Accruals
2
3
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.3%
-3.67%
26.76%
Free Cash Flow
-62.67%
-21.66%
-112.64%
Net Income, GAAP
-11.96%
-13.59%
-88.18%
Sales/Revenue/Turnover
7.65%
-0.44%
27.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
6
7
6
4
23
2017
4
5
5
15
29
2018
3
3
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.05
-0.05
-0.05
-0.08
-0.24
2017
-0.07
-0.06
-0.05
- -
-0.03
2018
-0.08
-0.08
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChat
Sector
Healthcare
Industry
Biotechnology
Address
IPO Date
Jun 22, 2004
CIK
0001123979
Similar Companies
Entrada Therapeutics, Inc. (TRDA)
Ovid Therapeutics Inc. (OVID)
Arcutis Biotherapeutics, Inc. (ARQT)
Viking Therapeutics, Inc. (VKTX)
DICE Therapeutics, Inc. (DICE)
CNBX Pharmaceuticals Inc. (CNBX)
Business
Senomyx, Inc. (SNMX) develops and commercializes novel flavor ingredients and high-intensity sweeteners for the food, beverage and ingredient supply industries using proprietary taste receptor-based technologies that amplify sweet, savory, bitter, cooling and salt tastes; its core products include savory flavor enhancers such as S6201 for umami enhancement, sweet taste modulators like S2383 for sucralose and S6973 for sucrose reduction, bitter blockers for beverages and artificial sweeteners, cooling agents for oral care products, and natural sweeteners derived from monk fruit fermentation such as Siratose. Firmenich SA, a Swiss flavors and fragrances giant, acquired Senomyx in September 2018 for $1.50 per share or approximately $75 million following a strategic review amid liquidity challenges, integrating its research into Firmenich's North America R&D and commercializing products through its Taste Platform; post-acquisition, Senomyx operates as part of the combined dsm-firmenich entity formed in 2023 without further independent public trading activity or major standalone developments. Founded in 1998 as Ambryx, Inc. in La Jolla, California and renamed Senomyx in 2000, the company is headquartered in San Diego and previously collaborated with partners including PepsiCo, Nestlé, Coca-Cola, Campbell Soup, Ajinomoto and Firmenich on flavor programs targeting reduced sugar, salt and MSG levels while maintaining taste profiles for global packaged goods markets.